Discussions with leaders: Frank Bengel talks with Jeroen Bax, an internationally recognized leader in integrating nuclear imaging and cardiology in clinical practice.
Page 1455
Single-cell radiotracing: Bartos and colleagues from Germany and Korea describe the process for single-cell radiotracer allocation via immunomagnetic cell sorting and provide examples of promising applications in neuroscience, oncology, and radiochemistry.
Page 1459
α-Synuclein PET and PD: Seibyl looks at the rationale for development of an α-synuclein–targeting PET agent in Parkinson disease and at the promise of such an agent for imaging and as part of therapeutic regimens.
Page 1463
Dosimetry in radiopharmaceutical therapy: O’Donoghue and colleagues provide an educational overview of current radiopharmaceutical therapy in the context of dosimetry, including internal dosimetry methods, incorporating dosimetry calculations into therapy, patient-specific dosimetry workflow, and future prospects.
Page 1467
Single-domain antibody theranostics: Wei and colleagues offer a focused summary of the latest developments in single-domain antibody–derived agents and propose strategies that can be used to improve the theranostic value of these agents.
Page 1475
Addressing PSMA controversy: Pomykala and colleagues respond to recent commentary in the literature questioning both the utility of prostate-specific membrane antigen PET imaging in patient selection for PSMA-targeted therapy and its use in staging and disease prediction.
Page 1480
PSMA PET/CT screening and VISION: Sartor provides perspective on the use of prostate-specific membrane antigen PET/CT in selection of patients for PSMA-targeted therapy through the lens of the VISION trial protocol, criteria, and results.
Page 1482
VISION-ineligible patient outcomes: Hotta and colleagues assess the outcomes of patients with metastatic castration-resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen who would have been screen failures based on PSMA PET/CT criteria in the VISION trial.
Page 1484
rhPSMA for therapy in prostate cancer: Wurzer and colleagues identify the prostate-specific membrane antigen–targeted radiohybrid ligand with the most favorable pharmacokinetics for 177Lu-radioligand therapy.
Page 1489
225Ac-PSMA in the post-ADT setting: Sathekge and colleagues report on treatment outcomes and survival using this novel agent immediately after androgen deprivation therapy in a series of patients with metastatic castration-resistant prostate carcinoma.
Page 1496
177Lu-DOTATATE in chronic kidney disease: Alsadik and colleagues investigate the efficacy and safety of 177Lu-DOTATATE in neuroendocrine tumor patients with reduced renal function.
Page 1503
SSTR2 heterogeneity assessed by CoV: Fonti and colleagues test the utility of the coefficient of variation from 68Ga-peptide PET/CT in evaluation and quantification of somatostatin receptor subtype 2 expression heterogeneity in patients with neuroendocrine tumors and metastatic lesions.
Page 1509
DNA damage after 131I therapy: Signore and colleagues explore whether thyroid remnant ablation with low activities of 131I is associated with DNA damage by evaluating the CometAssay, micronuclei, and chromosome aberrations with multicolor fluorescent in situ hybridization.
Page 1515
PD-L1 PET imaging in SCCHN: Verhoeff and colleagues report on 89Zr-DFO-durvalumab (anti–programmed death ligand 1) PET/CT imaging in patients with recurrent or metastatic squamous cell carcinoma of the head and neck before monotherapy with durvalumab.
Page 1523
Interobserver variability in PSMA PET/CT: Hagens and colleagues document the interobserver variability of 3 frequently used clinical radiotracers targeting the prostate-specific membrane antigen (18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11) in primary prostate cancer staging.
Page 1531
18F-PFPN PET and malignant melanoma: Zhang and colleagues detail the biodistribution and radiation dosimetry of 18F-PFPN in healthy volunteers and examine its diagnostic utility in patients with malignant melanoma.
Page 1537
223Ra-induced transient myelotoxicity: Parlani and colleagues explore the consequences of 223Ra treatment on bone marrow biology in a preclinical model.
Page 1544
In vivo imaging of reactive astrogliosis: Villemagne and colleagues characterize the clinical performance of 18F-SMBT-1, a novel MAO-B PET tracer, as a potential surrogate marker of reactive astrogliosis in neurodegeneration.
Page 1551
Reactive astrogliosis in aging and AD: Villemagne and colleagues assess the clinical performance of 18F-SMBT-1 PET across the Alzheimer disease continuum as a potential surrogate marker of reactive astrogliosis and early neurodegeneration.
Page 1560
Tracking innate immune activation: Lucot and colleagues investigate translocator protein 18 kDa PET plus PET imaging of the triggering receptor expressed on myeloid cells for detection of innate immune responses in a mouse model of dopaminergic neuron degeneration.
Page 1570
Total-body PET/CT in arthritis: Abdelhafez and colleagues detail the performance of an ultra-low-dose, 18F-FDG total-body PET/CT protocol for evaluating systemic joint involvement in autoimmune inflammatory arthritides and correlate results with joint-by-joint rheumatologic examination and standardized rheumatologic outcome measures.
Page 1579
PET and IBD: Seo and colleagues describe studies conducted to elucidate whether 18F-FSPG PET imaging of antiporter system xC− of immune cells can accurately assess inflammatory bowel disease activity in murine models and patients.
Page 1586
18F-FDG fetal dosimetry and PET/MRI: Zanotti-Fregonara and colleagues analyze data from 11 women injected with 18F-FDG for cancer staging and scanned with PET/MRI during the first 2 trimesters of pregnancy.
Page 1592
Toward broader 68Ga-citrate use: Suilamo and colleagues study the kinetics and dosimetry for PET applications in inflammatory and infectious diseases and cancer.
Page 1598
Data-driven motion correction in brain PET: Spangler-Bickell and colleagues present a reader-based evaluation and atlas-based quantitative analysis of a fully data-driven motion correction approach for brain PET in a clinical cohort.
Page 1604
PET/MRI and PET/CT radiomics harmonization: Leithner and colleagues determine whether ComBat harmonization improves 18F-FDG PET radiomics-based tissue classification in pooled PET/MRI and PET/CT datasets.
Page 1611
- © 2022 by the Society of Nuclear Medicine and Molecular Imaging.